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A B S T R A C T
U-47,700 is a synthetic opioid that emerged on the novel psychoactive substance market a few years ago.
After incorporating the substance into the urine UPLC-TOF-MS screening used in post-mortem
toxicology, the drug was detected in 10 autopsy cases within routine case work. In all cases, the cause of
death was accidental poisoning by U-47,700 alone or in combination with other psychoactive substances.
The concentration of U-47,700 in the blood samples ranged between 0.15–2.0 mg/L with a median of
0.30 mg/L. In one of the cases with a U-47,700 concentration of 0.27 mg/L, no other psychoactive
substances were detected.
The stored TOF-MS analytical data from the year preceding the incorporation of U-47,700 into the
screening was reprocessed in order to search for more positive cases. The data-independent acquisition
of the original screening allowed for retrospective re-analysis of the full-scan data without additional
experiments on the actual sample. The retrospective data-analysis revealed two additional cases positive
for U-47,700.
The first mention of U-47,700 on a Finnish internet discussion forumwas in March 2015. After having been
detected in several death cases, the drug was put under national control in November 2016 and the last
fatality occurred in 2017. The toxic lifespan of U-47,700 thus lasted for approximately 2 years in Finland.
Forensic and clinical laboratories need to rapidly adjust their screening procedures in order to adapt to
the continuously expanding field of novel psychoactive substances. Retrospective data-analysis is a
practical tool for monitoring the emergence of new substances onto the market.
© 2019 Elsevier B.V. All rights reserved.
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Opioids are commonly abused by users of illegal drugs, and they
account for the majority of fatal poisonings worldwide [1,2]. In
Finland, the opioid most commonly implicated as the cause of
death is buprenorphine, a semi-synthetic partial agonist at the m-
opioid receptor, whereas heroin abuse and deaths are rare. Also
other medicinal opioids used in the treatment of pain are
frequently detected in fatal poisoning cases, often together with
other psychoactive substances.
In addition to medicinal opioids, recent years have brought new
opioids onto the illicit drug market; opioids that have never been
approved for medical use. One of these is U-47,700 (3,4-dichloro-
N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide) (Fig. 1), a
highly selective m-receptor agonist originally developed by the* Corresponding author at: Forensic Toxicology Unit, National Institute for Health
and Welfare, Helsinki, Finland.
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0379-0738/© 2019 Elsevier B.V. All rights reserved.company Upjohn in 1970s [3]. Since 2016, several reports have
been published on serious adverse effects associated with U-
47,700, including death cases [4–15].
The emergence of new psychoactive substances (NPS) is a
challenge for forensic and clinical laboratories since new
substances enter the drug market in an ever escalating pace.
Acquiring reference material for each NPS is hardly sensible due to
financial reasons or due to the fact that these substances are not
readily available. In traditional toxicological screening it is only
possible to find those substances that are looked for. It is
complicated to estimate whether a certain NPS is of relevance in
one’s own setting and should be incorporated into the screening.
Using time-of-flight mass spectrometry (TOF) with data-indepen-
dent acquisition, the full precursor ion data set as well as the full
fragment ion data set are acquired in a single run. Thus it is possible
to revisit previously analysed raw data and look for new
information without the need to run the samples again.
LC-TOFMS has gained popularity in the forensic field due to the
accurate mass and high mass resolution capabilities combined
with easily expandable reference databases but relatively few
Fig. 1. Structure of U-47,700.
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reprocess the historic data [13,16–18]. In this project we aimed to
study the lifespan of U-47,700 in Finland, taking advantage of the
possibility to retrospectively reanalyse the stored data.
2. Material and methods
Urine and femoral blood samples from unexpected death cases
were collected at autopsies and stored refrigerated until analysis.
2.1. Adding U-47,700 to the TOF-MS database
A sample of seized U-47,700 was generously provided by the
Finnish Customs Laboratory in March 2016. A standard solution
with the approximate concentration of 1 mg/mL of U-47,700 was
injected into the system twice (two parallel injections). The
precursor exact mass, retention time and assigned fragment ions
information of the substance was added to the TOF-MS analyte
database. The following criteria were met for the two injections:
DRt < 0.3 min, mass precision of the precursor ion <3 mDa, and
mass precision of the qualifier ion <5 mDa. As customary for
updating the analyte database, the fragmentation pattern of U-
47,700 was further confirmed by the ACD/MS Fragmenter software
(Advanced Chemistry Development, Toronto, Canada) and the
Smart Formula 3D feature of Bruker Data Analysis software (Bruker
Daltonics GmbH, Bremen, Germany).
The exact mass of the precursor protonated molecule added to
the database was m/z 329.1182, and the exact masses of the
characteristic fragment ions were m/z 284.0603 and m/z 203.9977.
The primary fragment (m/z 284.0603) used as qualifier ion for U-
47,700 is also a fragment of the structural isomer AH-7921 —
another abused opioid. However, in the current procedure, these
two analytes are chromatographically separated (retention time
difference >0.35 min). Ion ratios of the two substances are different
and the fragment 284.0603 is not the most abundant fragment of
AH-7921. Consequently, the qualifier ions assigned for AH-7921
(m/z 172.9552 and 189.9821) are different from those of U-47,700.
In addition, m/z 189.9821 is unique for AH-7921, which further
minimizes the risk of false identification.
After the first detection of the substance in biological samples,
an official reference standard was purchased from Chiron
(Trondheim, Norway) enabling appropriate quantitative analysis.
2.2. Sample preparation and qualitative screening with UPLC-TOFMS
Urine samples were screened for U-47,700 by ultra-high
performance liquid chromatography coupled with high-resolution
time-of-flight mass spectrometry (UPLC-TOFMS). The screening
method is described in detail elsewhere [19]. In short, after
hydrolysis and solid phase extraction, the extracts were dissolved
in a mixture of methanol and 0.1% formic acid (45:55) without
concentrating the samples. The extracts were injected into theUPLC-TOFMS system consisting of a Waters Acquity UPLC coupled
with a Bruker MicroTOF Q II. Data were acquired in full-scan MS
and bbCID (broad-band collision-induced dissociation) MS modes
by switching the collision energy between 8 eV (precursor MS data
acquisition) and 30 eV (fragment bbCID MS data acquisition).
The UPLC-TOFMS screening provided full-scan data that was
subsequently processed against the in-house analyte database
consisting of hundreds of medicinal drugs, drugs of abuse, NPS and
metabolites. The principles of the database search have been
published elsewhere [19].
2.3. Quantitative analysis with GC–MS
Quantification of U-47,700 in femoral blood and urine was
performed by gas chromatography–mass spectrometry (GC–MS),
using a method originally developed for the determination of
MDPV [20]. The GC–MS analysis was performed by selected ion
monitoring, using four ions (m/z 125 (target), 84, 145, and 173) for
U-47,700. The heptafluorobutyric acid derivative of MDMA-d5 (m/
z 254, 210) was used as an internal standard.
Linearity of the method was studied by constructing calibration
curves in blood and urine, consisting of seven concentration points
over the range of 0.02–2.5 mg/L with five parallel measurements in
each point. The correlation coefficient (r2) was 0.991. Intra-day
accuracy (bias) and precision was <11% and <6% CV (at 0.02–
2.5 mg/L), respectively. Between-day accuracy and precision were
measured on seven separate days over a period of four weeks.
Between-day accuracy (bias) at 0.1 and 1.0 mg/L was 10% and 16%,
respectively, and between-day precision 12% and 16% CV,
respectively. The limits of detection (LOD) and quantification
(LOQ) were 0.01 and 0.02 mg/L, respectively
The GC–MS-method was able to chromatographically separate
U-47,700 from the structural isomer AH-7921 (retention time
difference 0.35 min).
2.4. Retrospective data-analysis
Retrospective analysis of the stored TOF-MS data for the one-
year period prior to inclusion of U-47,700 in the database was
conducted in the same way as the original data analysis, but the
analyte database had in the meantime been updated with new
analytes, including U-47,700.
Reanalysis of the raw data was rather time-consuming due to
the high number of cases and, consequently, the volume of data to
be reanalysed. The software was let to reprocess the data
overnight, one month at the time.
3. Results and discussion
U-47,700 was first detected in a post-mortem sample in April
2016; one month after the drug had been included in the screening.
U-47,700 was subsequently detected in seven other post-mortem
cases in 2016. Consequently, U-47,700 was controlled under the
Narcotics Act in Finland in November 2016. In 2017, the drug was
detected twice but there were no positive autopsy cases in 2018.
Details of the ten cases positive for U-47,700 are given inTable 1. In all
of the 10 cases, the cause of death was accidental poisoning by U-
47,700 alone or in combination with other psychoactive substances.
All of the deceased positive for U-47,700 were male, and their
mean age (range) was 26 (23–31) years. The median (range) blood
concentration of U-47,700 was 0.30 (0.15–2.0) mg/L. In most cases
other psychoactive drugs were detected along with U-47,700.
According to the background information, in most cases the
deceased had a history of drug abuse. The concentrations detected
in these 10 cases were similar to those reported by Mohr et al. [6],
Rojek et al. [14] and Smith et al. [15] who found median U-47,700
Table 1
Details of U-47,700-positive cases in 2016 and 2017.
Case Age Gender BAC Concentration of U-47,700 Other drugs detected in blood (mg/L)
g/kg Blood (mg/L) Urine (mg/L)
1 23 Male 3.00 0.22 0.02 –
2 27 Male – 0.32 0.03 MDMA 2,4; amphetamine 0,67; pregabalin 40; alprazolam 0,006
3 28 Male – 0.19 posit N-MBZP 0,092; BZP 0,0081; m-CPP 0,020; phenazepam 0,26; alprazolam 0,034;
4 24 Male – 0.27 0.40 –
5 29 Male 2.00 0.19 0.06 Buprenorphine 0.53 mg/L; 7-aminoclonazepam 0.18; pregabalin 3.9; cannabis positive
6 23 Male 0.75 0.37 0.10 7-aminoclonazepam 0.16
7 25 Male – 0.15 0.23 Pregabalin 19; alprazolam 0.013; lorazepam 0.011; THC 6.4 mg/L
8 25 Male – 2.00 0.89 Buprenorphine 1 mg/L; 7-aminoclonazepam 0.14
9 31 Male – 0.64 0.57 α-PVP 0.34; THC 1.1 mg/L; pregabalin 11; alprazolam 0.030; tramadol 0.47; diazepam 0.059;
olanzapine 0.42
10 23 Male – 0.96 2.20 Amphetamine 0.17; 7-aminoclonazepam 0.24; alprazolam 0.009; buprenorphine <0.5 mg/L
R1 27 Male – – Posit Etizolam 0.040; 7-aminoclonazepam 0.083; THC-COOH 20 mg/l
R2 32 Male – – Posit Amphetamine 0.32; etizolam <0.025
Fig. 2. U-47,700 in Finland.
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(N = 12), and 0.126 mg/L (N = 15) respectively.
Among the studied cases, there was one case in which no other
psychoactive substances, besides U-47,700, were detected (Case 4,
Table 1). The blood concentration of U-47,700 in this case (0.27 mg/L)
did not significantly differ from the median U-47,700 concentration.
However, regardless of the blood concentration, the toxicological
significance of detecting U-47,700 or any other opioid is profoundly
connected to the state of opioid tolerance the victim may have
possessed, as well as the route of administration and other findings.
Thus, defining a fatal concentration for a strong opioid, such as U-
47,700, is considered somewhat meaningless.
Retrospective re-analysis of the acquired TOF-MS data was
performed for all samples screened for illegal drugs within a one-
year period before inclusion of U-47,700 in the screening method. A
total of 1836 samples were reprocessed. The procedure resulted in two
additional positive findings of U-47,700. Details on these two cases are
presented in Table 1 (R1 & R2) and the toxic lifespan of U-47,700 inpost-mortem investigations in Finland is illustrated on a timeline in
Fig. 2. Unfortunately, at the time of the reprocessing, the original
sample material was no longer available and thus no quantitative
results are available. Interestingly, in both of the retrospectively
detected cases, etizolam was detected together with U-47,700.
Retrospective re-analysis is a tool often mentioned as a useful
option but relatively seldom used in forensic laboratories. To our
knowledge, only in a handful of cases retrospective re-analysis has
been successfully used to detect drugs in previously analysed
biological samples. Partridge et al. was able to detect several NPS in
a death case after having updated the in-house database [13].
Noble et al. screened thousands of blood samples for fentanyl
derivatives using retrospective re-analysis of previously acquired
data [18]. Retrospective data processing has also been used to
screen for metabolites in samples in which the parent compound
has already been identified [17,21,22].
There are several factors affecting the lifespan of an NPS.
Considering the total number of all different NPS reported, only a
88 P. Kriikku et al. / Forensic Science International 300 (2019) 85–88few of them have gained considerable prevalence or media
attention. It has been shown that the legal status of a substance in
the end-users’ country has a considerable influence on the interest
in the drug and on the corresponding harms [23,24].
Drug marketplaces on the hidden web are increasingly used for
anonymous sale of drugs [25], and the earliest indication of the
possible appearance of a new substance might indeed be
evidenced on the hidden web [26]. One study found that vendors
selling NPS had short lifespans, and while individual NPS had
longer lifespans, only a quarter of the studied substances were
generally available over a period of one year [25]. Post-mortem
toxicology usually contributes to the monitoring of emerging NPS
only when their use has become prevalent in the society. However,
potent opioids are exceptional in this respect, as has been
evidenced with the case of 3-methylfentanyl in Finland, where
all the findings of the drug were from fatalities that occurred
within a short period of time [27].
Another important factor affecting the lifespan of a particular
NPS is the drug supply in the country of origin. Concerning U-
47,700, the substance was added to China’s list of controlled
substances as of July 1, 2017, which coincides with the end of the
toxic epidemic in Finland.
In addition to laboratory measures, a number of other methods
for monitoring the appearance and use of NPS are being used. These
include e.g. monitoring the online user forums, user questionnaires,
information from poisons information services, and international
early warning systems [28]. As demonstrated in the case of U-47,700
in Finland and in the few studies published before, retrospective
data-analyses can be a valuable tool in assessing the time point at
which the drug has entered the market [13,16].
4. Conclusion
A series of cases positive for an NPS opioid U-47,700 was
detected in post-mortem investigations within a relatively short
time period prompting the idea of retrospectively re-analysing the
data before the first detection. The re-analysis resulted in two
additional cases. The post-targeted screening approach enabled
relatively easy access to the full-scan data acquired before
incorporating the substance into the screening. Retrospective data
analysis can be especially useful when monitoring the lifespan of
NPS in clinical and forensic settings.
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